Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

by Grantina, Ineta , Simões, Eric A.F , Chang, Yue , Madhi, Shabir A , Cabañas, Fernando , Garcia-Garcia, Maria L , Griffin, M. Pamela , Takas, Therese , Domachowske, Joseph , Nguyen, Kim A , Atanasova, Victoria , Yuan, Yuan , Furuno, Kenji , Brooks, Dennis , Leach, Amanda , Mankad, Vaishali S , Villafana, Tonya

in Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - pharmacokinetics / Antibodies, Monoclonal, Humanized - therapeutic use / Antiviral Agents - adverse effects / Antiviral Agents - pharmacokinetics / Antiviral Agents - therapeutic use / Birth Defects / Cardiovascular disease / Childhood Diseases / Chronic Disease / Congenital diseases / Coronary artery disease / Coronaviruses / COVID-19 / Diagnostic tests / Global Health / Gynecology / Gynecology General / Heart diseases / Heart Diseases - complications / Humans / Infant / Infant, Newborn / Infant, Premature / Infant, Premature, Diseases - prevention & control / Infants / Infectious Disease / Injections, Intramuscular / Life Sciences / Lung diseases / Lung Diseases - complications / Monoclonal antibodies / Neonatology / Obstetrics / Palivizumab - therapeutic use / Pediatrics / Pharmacokinetics / Respiratory syncytial virus / Respiratory Syncytial Virus Infections - complications / Respiratory Syncytial Virus Infections - prevention & control / Safety / Severe acute respiratory syndrome / Severe acute respiratory syndrome coronavirus 2 / Thrombocytopenia / Viral Infections

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

2022

Confirm

Do you wish to request the book?

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

Grantina, Ineta,

Simões, Eric A.F,

Chang, Yue,

Madhi, Shabir A,

Cabañas, Fernando,

Garcia-Garcia, Maria L,

Griffin, M. Pamela,

Takas, Therese,

Domachowske, Joseph,

Nguyen, Kim A,

Atanasova, Victoria,

Yuan, Yuan,

Furuno, Kenji,

Brooks, Dennis,

Leach, Amanda,

Mankad, Vaishali S,

Villafana, Tonya

2022

Overview

Nirsevimab is a monoclonal antibody targeting respiratory syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to receive palivizumab, including those born preterm (at 35 weeks of gestation or less) and those with congenital heart disease or chronic lung disease of prematurity. No safety concerns were identified.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Antibodies, Monoclonal, Humanized - adverse effects

/ Antibodies, Monoclonal, Humanized - pharmacokinetics

/ Antibodies, Monoclonal, Humanized - therapeutic use

/ Antiviral Agents - adverse effects

/ Antiviral Agents - pharmacokinetics

/ Antiviral Agents - therapeutic use

/ Birth Defects